Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Toggle navigation
Contact Us
Subscribe
Promote Your Event
e-Edition
Privacy Policy
Terms of Service
Local Weather
Home Delivery
Submission Forms
News
Local News
The Leader
Heartland News
Sports
Entertainment
Local Events
Multimedia
Photo Galleries
Videos
Obituaries
Classifieds
Real Estate
Property for Rent
Cars & Vehicles
Jobs
Items for Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place an ad
Legals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ionis Pharmaceuticals
(NQ:
IONS
)
48.85
+0.51 (+1.06%)
Streaming Delayed Price
Updated: 9:56 AM EST, Nov 29, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ionis Pharmaceuticals
< Previous
1
2
3
4
5
6
7
Next >
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
May 04, 2023
Via
Benzinga
Recap: Ionis Pharmaceuticals Q1 Earnings
May 03, 2023
Via
Benzinga
Ionis Pharmaceuticals's Earnings Outlook
May 02, 2023
Via
Benzinga
Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA
April 26, 2023
The FDA approved Biogen Inc's (NASDAQ:
Via
Benzinga
What's Going On With Biogen Stock Tuesday?
April 25, 2023
Biogen Inc (NASDAQ: BIIB) shares are trading lower Tuesday. The company reported first-quarter results before the bell and the FDA approved its ALS therapy Tuesday afternoon.
Via
Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
April 11, 2023
Via
Benzinga
Analyst Ratings for Ionis Pharmaceuticals
March 21, 2023
Via
Benzinga
Ionis Pharmaceuticals's Earnings Outlook
February 21, 2023
Via
Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
January 19, 2023
Via
Benzinga
Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs
April 25, 2023
Via
Benzinga
3 Biotech Stocks to Sell Before They’re 6 Feet Under
April 24, 2023
Biotech stocks with no earnings, no cash, and no path to profit will have no chance at survival. Here's three such biotech stocks to avoid.
Via
InvestorPlace
AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression
April 24, 2023
Via
Benzinga
Could This Rare-Disease Drug Candidate Become a Blockbuster?
April 19, 2023
This drug candidate could be a great treatment option for patients with a potentially deadly disease.
Via
The Motley Fool
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward'
April 12, 2023
SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy...
Via
Benzinga
AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review
March 27, 2023
Via
Benzinga
The Latest Analyst Ratings for Ionis Pharmaceuticals
December 21, 2022
Via
Benzinga
Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed
December 13, 2022
Via
Benzinga
4 Analysts Have This to Say About Ionis Pharmaceuticals
November 10, 2022
Analysts have provided the following ratings for Ionis Pharmaceuticals (NASDAQ:IONS) within the last quarter:
Via
Benzinga
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
March 23, 2023
The companies are focusing on a small population of ALS patients with a genetic mutation.
Via
Investor's Business Daily
FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder
March 23, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
March 21, 2023
Via
Benzinga
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year
March 16, 2023
Via
Benzinga
Analyst Says Ionis' Additional Hereditary Angioedema Study Data Supports 'Highly Competitive Profile'
February 21, 2023
Via
Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
February 02, 2023
The company that remains still has a large pipeline of non-migraine assets.
Via
Investor's Business Daily
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
January 09, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
January 04, 2023
From
Biogen Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022
December 21, 2022
Via
Benzinga
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
November 16, 2022
Neurodegenerative disorders could mean big bucks for some biotechs.
Via
Investor's Business Daily
Phillips 66 To Rally 25%? Here Are 5 Other Price Target Changes For Thursday
November 10, 2022
Via
Benzinga
Ionis Regains Rights To Thrombosis Candidate From Bayer
November 04, 2022
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.